Introduction

I
n Canada, breast cancer has been the most commonly diagnosed cancer and the second most common cause of cancer deaths for women. 1, 2 Annually over 20 000 new breast cancer cases were projected from 2010 to 2015, corresponding to an incidence rate of over 100 cases per 100 000 women. 1 The incidence rate rose from 1982 to the early 1990 s, and has remained fairly constant since then.
Although a reduction in the mortality rate is one of the targets for cancer prevention and control, estimating mortality rate alone cannot quantify the burden of loss due to mortality. 3 Analyzes of crude and age-standardized mortality rates are important determinants of the nation's health status as they have been used to set priorities and measure progress towards the achievement of public health goals; however, they often fail to tell the entire story of temporal changes in premature mortality. Alternative measures have been proposed to reflect premature mortality trends that provide a more accurate picture by weighting deaths occurring at younger ages more heavily than those occurring in older populations. One of these measures is years of life lost (YLL) that indicates how much the life of a patient is shortened because of death from a particular condition or injury. [3] [4] [5] Given little is known about whether the recent reduction in mortality rates for breast cancer have impacted the burden of premature deaths over time, we investigated whether there has been improvement in premature mortality due to breast cancer among Canadian women from 1980 through 2010 and have demonstrated the utility of a novel measure, the average lifespan shortened (ALSS), in assessing YLL over time and across populations.
Methods
Study population
The number of female breast cancer deaths in 5-year age groups was obtained from the World Health Organization (WHO) mortality database 6 for the period of 1980-2010. During this period, causes of death were coded according to the International Classification of Diseases and Injuries (ICD) 9th Revision (ICD-9) from 1980 to 1999; and to the10th Revision (ICD-10) from 2000 and onward. Breast cancer was coded as 174 according to the ICD-9 and C50 in ICD-10. We obtained Canadian population data from Statistics Canada for the study period. 7 
Life tables for Canada
Statistics Canada reports life tables, which show mortality rate, survival rate and remaining life expectancy at different ages. Over a 30-year period, several versions of life tables were made available by Statistics Canada. 8 In this study, the following life tables were used to estimate premature mortality: the 1980-82 life tables for  1980-84; the 1985-87 life tables for 1985-89; the 1990-92  life tables for 1990-94; the 1995-97 life tables for 1995-99; the  2000-02 life tables for 2000-04 and the 2005-07 life tables for  2005 and onward. The life expectancy at birth increased from 78.9 years to 83.4 in women over the 30 year period.
Statistical analyzes
The WHO database provides the aggregated number of deaths by each of 18, 5-year age groups that include 0-4, 5-9, 10-14, 15-19, 20-24, 25-29, 30-34, 35-39, 40-44, 45-49 , 50-54, 55-59, 60-64, 65-69, 70-74, 75-79, 80-84 and 85+ years old. We calculated the agestandardized rates (ASRs) of breast cancer mortality per 100 000 women for each study year using the direct method of standardization according to the World Standard Population. We applied YLL computation according to the Global Burden of Disease and Injury (GBD) Project where detailed methodology for YLL calculation has been described. 9, 10 Briefly, YLL is calculated by multiplying number of deaths with the age-specific expectancy derived from life tables. We calculated the adjusted rate of YLL per 1000 women according to the World Standard Population to assess the burden of life loss due to breast cancer relative to the entire female population. Average years of life lost (AYLL) was estimated by dividing the total YLL over the total number of deaths due to breast cancer in each calendar year. We also calculated a new measure, ALSS that is expressed by a ratio of YLL relative to expected lifespan based on relevant national life tables. For instance, a given woman who died in the year 2000 at 60 years of age would have lost 24.7 years according to the 2000 female life table. Therefore, her lifespan was shortened by 29% resulting from her 24.7 YLL over her expected lifespan of 84.7 years of age. The ALSS indicates an average percentage of lifespan shortened among all women who died from breast cancer. Statistical analyzes were performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA). Table 1 provides information on breast cancer deaths from 1980 to 2010 in Canada. Despite the number of breast cancer deaths increasing from 3472 deaths in 1980-84, 4978 in 2010, the ASR for mortality decreased from 23.2-14.2 per 100 000 women during the same period. Although fluctuated occurred over the 30-year period, the ASRs showed a steadily decreasing trend throughout the study period. Among all age categories, breast cancer deaths occurred predominantly in women aged 50-59 and 60-69 years starting from the 1980 s until the middle of 1990 s. Thereafter, the deaths occurred gradually to older age groups.
Results
The total YLL increased from 72 371 years in 1980 to 91 332 years in 2010 (table 2) . In contrast, when we adjusted for aging of the population, we observed a steady reduction in the adjusted rates of YLL throughout the study period, and the rates fell from 5.3-3.3 years per 1000 women in 1980 and 2010, respectively. Consequently, AYLL decreased from 20.8 years in 1980 to 18.3 years in 2010 resulting in a decrease in ALSS from one-fourth (24.6%) of their expected lifespan at the beginning of the study period to about one-fifth (20.5%) at the end of the period. In other words, on average, women with breast cancer lived 4.1% more of their life at the end of this period relative to those in earlier years of the study period.
Discussion
In the present study, we aimed to investigate whether there was any improvement of premature breast cancer mortality among Canadian women over a 30 year period and demonstrated the benefit of utilizing several measures of premature mortality. The results show that even though the number of breast cancer deaths and the overall YLL increased, the age-adjusted rate of YLL decreased. In addition, the average lifespan of women with breast cancer was prolonged by 4.1% according to our new ALSS measure. Sparsely used before the 1990 s, 11,12 measures of premature mortality are being reported more extensively following the inception of the GBD Project.
9,10,13-15 However, variation in methods used to calculate YLL make results incomparable between studies. Two major algorithms for YLL computation exist to date. The first one is to use a fixed age threshold for the computation of YLL, typically 65, 70 or 75 years. 11, 12, 16, 17 According to this threshold approach, only people who die before that age threshold are considered 'premature' deaths, while those who die of cancer but live beyond the threshold are not 'premature' any more and are therefore not accounted for in the YLL. Table 1 shows that this approach would disregard about 30% of deaths in the 1980 s and 50% in 2010, if age 70 was applied as the limit. Consequently, any health programs that prevent or delay deaths after that age threshold are not reflected in the measure. In contrast, YLL in the present study was based on a comparison of the actual age at death to the corresponding life expectancy from the national normative life tables. We did not apply the concept of either age weighting or time discounting described in the original GBD Project since our subsequent measures required actual estimates. People who die at any age therefore contribute to the YLL and, death at any age due to cancer is considered premature. On this basis, efforts to prolong life at any age for a cancer patient would be valuable. These differences in YLL methodology raise a need for caution when attempting to compare results between studies.
From 1980 to 2010, the female population in Canada increased from 12 to 17 million resulting in an increase in the number of breast cancer deaths observed in our study. However, we observed that the ASRs decreased by about 40% throughout the study period.
Interestingly, the AYLL was reduced by 2 years in 2010 compared to 1980, while female life expectancy at birth increased by about 4 years during this period. 8 This implies that the absolute lifespan gain was 6 years. In other words, the average lifespan of women with breast cancer was 6 years longer in 2010 compared to that in 1980.
In this study, we presented a new measure, the ALSS that, to the best of our knowledge has not been published previously, to examine premature mortality in breast cancer women in Canada. This measure is simply the percentage of how much on average women with breast cancer died earlier than expected length of lifespan according to national life tables. Therefore, regardless of changes to the life tables, the ALSS merely reflects the percentage of the lifespan that was lost relative to the expected length of life for a woman without breast cancer. The findings of our study suggest that Canadian women with breast cancer lost about one-fourth of their life in 1980, whereas they lost only one-fifth 30 years later; this measure is very intuitive and can be implemented easily for longitudinal monitoring of premature mortality for any chronic condition.
In the present study, several measures were used to show favorable trends in premature mortality from breast cancer among Canadian women. The ASR is a conventional measure and has been used widely in monitoring the pattern of mortality over time. The total YLL is proportional to the total number of deaths, and it indicates the total volume of lost life at the national level. The adjusted YLL rates decreased by approximately 40% in line with the decrease in the ASRs. The AYLL shows an absolute improvement of 2 years, while the ALSS reports a relative improvement of approximately 5% of life. Hence, all these life lost measures could be considered as a set of tools for periodically examining trends of premature deaths over time. Diagnosis of breast cancer at an earlier stage results in better survival and hence early detection is one of the most effective strategies for control of this condition. 18, 19 The International Cancer Benchmarking Partnership was conducted to examine survival by stage in Australia, Canada, Denmark, Norway, Sweden and the UK. The results show that 3-year age-standardized net survival rates were close to 100% for stage I breast cancer in most countries, while the rates were around 80% for stage III, and between 30-40% for stage IV. 19 Early detection can be achieved through breast health awareness and screening. Multiple studies have suggested that screening reduces the risk of dying from breast cancer. 20, 21 In Canada, British Columbia was the first province to implement a population-based breast cancer screening program with mammography. All other provinces started providing similar screening programs in the early 1990 s. 22 In 1996, interprovincial participation rates were low ranging from 10 to 54% among the target women aged 50-69. 22 Despite a national participation rate target set at 70%, the overall rate was only 40% between 2004 and 2006. 23 The reduction in the life loss measures demonstrated in this study are likely in part due to the introduction and uptake of population-based mammography programs. Therefore, it is possible that thousands of YLL could have been saved if provincial screening programs had managed to comply with mammography targets for women aged between 50 and 74. 24 The Cancer Intervention and Surveillance Modelling Network (CISNET) 25 has reported on seven statistical models developed to estimate the impact of screening mammography relative to adjuvant therapies on breast cancer mortality in the United States from 1975 to 2000. In terms of adjuvant therapies, both chemotherapy and tamoxifen were considered. For the mortality reduction observed in this time frame, 28-65% was attributable to mammography and the remainder to adjuvant treatments. From the 1970's to the current era, there has been tremendous change in the management of early breast cancer. The CISNET collaborators found that for node positive breast cancer, prescription of adjuvant chemotherapy in post-menopausal women increased from almost 0% in 1975 to 80% in 2000. Adjuvant chemotherapy has become a standard recommendation for pre-and post-menopausal women with higher risk node negative and node positive breast cancer. [26] [27] [28] Meta-analyzes have confirmed improved outcomes with anthracycline and taxane-based regimens 29 plus adjuvant trastuzumab for HER2 over-expressing disease 30 with the latter two treatments potentially impacting the last decade of our analysis. With respect to tamoxifen, the CISNET collaborators reported increased use from essentially 0% in 1975-50% in 2000. 25 Approximately, 85% of all breast cancer is estrogen receptor positive and adjuvant hormonal therapy is now recommended to nearly all patients with node negative or node positive, estrogen receptor positive disease. 27, 28 Furthermore, cancer therapies are publicly reimbursed in our Canadian context. Apart from adjuvant chemotherapy and tamoxifen, mortality reduction may also have been influenced by increased application of adjuvant radiation post breast conserving surgery, 31 the introduction of adjuvant aromatase inhibitors for post-menopausal women with estrogen receptor positive breast cancer, 32 and more effective systemic therapies for metastatic breast cancer (i.e. aromatase inhibitors, new chemotherapeutic agents and trastuzumab). 33 
Conclusion
The present study reports that among Canadian women with breast cancer, a smaller proportion of life was lost on average at the end of the study period. The 'life loss' measures presented in the present study would be useful tools to monitor the trends in premature mortality in breast cancer and other chronic conditions, and can also be used as proxies for how effectively the health system functions with respect to early detection and treatment.
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